Value through Innovation20 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

18.10.2013

New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries

- For media outside the UK, U.S. and Canada
14.10.2013

Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval

- For non U.S. Media Only
08.10.2013

Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

- For media outside of the U.S.A., UK and Canada only
07.10.2013

Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin

- For media outside of the US, the UK & Canada only
07.10.2013

Ben Venue Laboratories, Inc. to Cease Production

30.09.2013

Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy

- For non U.S. Media Only
27.09.2013

Boehringer Ingelheim Animal Health achieves milestone: 500 million pigs benefit from Mycoplasma vaccination

26.09.2013

Boehringer Ingelheim significantly expands its production footprint in China

25.09.2013

GIOTRIF® (afatinib)* approved in Europe for patients with EGFR mutation positive lung cancer

- For non U.S. Media Only
24.09.2013

Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes

- For Non-US and Non-UK Media
24.09.2013

Pooled analysis data showed improvements in glycaemic parameters, body weight and blood pressure with investigational agent empagliflozin* in adults with Type 2 Diabetes


- For Non-US and Non-UK Media
23.09.2013

New poll highlights treatment priorities of European primary care physicians when managing Type 2 Diabetes

- Ex -US & Ex- UK Medical Media Only
19.09.2013

Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests

17.09.2013

Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound, empagliflozin* in various diabetes subpopulations

- Ex -US & Ex- UK Medical Media Only
17.09.2013

Volasertib* receives FDA Breakthrough Therapy designation for treatment of patients with acute myeloid leukaemia

- For non-U.S. media only
10.09.2013

Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals

- For media outside USA, UK and Canada only
09.09.2013

ERS Congress 2013
Phase III results: Once daily olodaterol* Respimat® provides effective and sustained improvements in lung function in patients with COPD1-3

- For media outside the UK, U.S. and Canada  
09.09.2013

ERS Congress 2013
New Phase III data presented for first time demonstrate: tiotropium* Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS treatment1

- For media outside the U.S., Canada and UK